Evgen Pharma PLC EVG
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- GBX 0.80
- Day Range
- GBX 0.83–0.83
- 52-Week Range
- GBX 0.70–4.05
- Bid/Ask
- GBX 0.75 / GBX 0.85
- Market Cap
- GBX 352.56 Mil
- Volume/Avg
- 195,000 / 1.4 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 2.62
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Evgen Pharma PLC is a UK-based clinical-stage drug development company. The company is focused on the development of sulforaphane-based compounds. Its core technology is Sulforadex, which synthesis and stabilizes the naturally occurring compound sulforaphane. Geographically, the company operates only in the United Kingdom. It is engaged in the treatment of breast cancer and Subarachnoid Haemorrhage.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 10
- Website
- https://www.evgen.com
Valuation
|
Metric
|
EVG
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.65 |
Price/Sales | 2.62 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
EVG
|
|---|---|
Quick Ratio | 10.39 |
Current Ratio | 10.39 |
Interest Coverage | — |
Quick Ratio
EVG
Profitability
|
Metric
|
EVG
|
|---|---|
Return on Assets (Normalized) | −53.62% |
Return on Equity (Normalized) | −65.59% |
Return on Invested Capital (Normalized) | −60.21% |
Return on Assets
EVG
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Bcfzyphtk | Jtny | $557.8 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Dffcwznvm | Lbdsd | $103.3 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Fhdplfry | Tmnlqkl | $98.8 Bil | |
MRNA
| Moderna Inc | Drrqcknb | Jbx | $38.8 Bil | |
ARGX
| argenx SE ADR | Rwwbcqxzk | Yjxz | $21.3 Bil | |
BNTX
| BioNTech SE ADR | Gtgrbsk | Mvnp | $20.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Dtfgmqb | Kqfkfc | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Sztwtrss | Ntyqw | $17.0 Bil | |
RPRX
| Royalty Pharma PLC Class A | Bxlgqspbm | Dtksjy | $12.4 Bil | |
INCY
| Incyte Corp | Qmtvwpyh | Vhfxjry | $11.9 Bil |